Australia TGA ARTG recordXEN 45 Glaucoma Treatment System - Glaucoma shunt
Australia TGA ARTG Registered Device · Abbvie Pty Ltd · Allergan · Class III · Started December 21, 2017
Good Name: Abbvie Pty Ltd - XEN 45 Glaucoma Treatment System - Glaucoma shunt
- Risk Class
- Class III
- Product Type
- Single Device Product
- ARTG Category
- General
- Start Date
- December 21, 2017
- Effective Date
- December 21, 2017
- Name
- Abbvie Pty Ltd
- Name
- Allergan
- Country
- United States of America
- Address
- 2525 Dupont Drive, Irvine, CA, 92612
The XEN Gel Implant is intended to reduce intraocular pressure in patients with primary open angle glaucoma where previous medical treatments have failed.
Access comprehensive regulatory information for XEN 45 Glaucoma Treatment System - Glaucoma shunt in the Australia medical device market through Pure Global AI's free TGA ARTG database. This Class III is sponsored by Abbvie Pty Ltd, manufactured by Allergan in United States of America. The device registration started on December 21, 2017.
This page provides complete registration details including sponsor information, manufacturer details, and regulatory compliance data from the official Australia TGA ARTG medical device database. Pure Global AI offers free access to Australia's complete medical device registry with 131,000+ devices, helping global MedTech companies navigate TGA regulations efficiently.